髂静脉支架与药物治疗慢性静脉疾病的随机双盲研究
本研究为随机双盲试验,纳入临床分级C3至C6且疼痛视觉模拟评分(VAS)>3的慢性静脉疾病(CVD)患者,将血管内超声(IVUS)显示髂静脉梗阻≥50%的患肢随机分为单纯药物治疗组与药物联合髂静脉支架组。6个月随访显示,支架组在疼痛评分、静脉临床严重程度评分及生活质量问卷上均显著优于单纯药物组,且无支架断裂或移位。
要点
- IVUS证实髂静脉梗阻≥50%的C3-C6慢性静脉疾病患者可考虑支架治疗
- 支架组6个月疼痛评分中位数由8降至2.5,单纯药物组由8降至7
- 支架组6个月一期通畅率92%、辅助一期通畅率96%、二期通畅率100%
核心结论
- 对有症状的慢性静脉疾病合并髂静脉梗阻患者,支架置入安全且较单纯药物治疗更有效缓解症状并改善生活质量。
研究设计与样本
- 随机双盲试验,207例慢性静脉疾病患者中58例(28%)符合入选标准,8例(14%)被排除;85条C3至C6患肢中51条(60%)经IVUS判定髂静脉梗阻≥50%并随机分组。
主要发现
- 支架组6个月VAS疼痛评分中位数由8降至2.5,单纯药物组由8降至7(P < .001)。
- 静脉临床严重程度评分支架组由中位数18.5降至11,单纯药物组由15降至14(P < .001)。
- 36项健康调查简表(0-100)总分支架组由中位数53.9升至85.0,单纯药物组由48.3升至59.8(P < .001)。
- 无支架断裂或移位,一期、辅助一期、二期通畅率分别为92%、96%、100%(中位随访11.8个月,范围6-18个月)。
关键数值与推荐
- 入选标准为临床分级C3至C6且疼痛视觉模拟评分>3。
- 随机分组依据IVUS显示髂静脉梗阻≥50%。
- 支架置入在随机患者中技术成功率100%。
临床怎么用
- 对C3至C6慢性静脉疾病患者,可先行IVUS评估髂静脉梗阻程度,对≥50%梗阻且有症状者考虑支架治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Iliac vein stenting has emerged as the procedure of choice in the treatment of iliac vein obstruction (IVO). However, clinical outcomes have never been studied by a randomized clinical trial. Our purpose was to compare medical and endovascular treatment results in symptomatic chronic venous disease (CVD) patients with significant IVO documented by intravascular ultrasound (IVUS). METHODS: Patients with Clinical, Etiology, Anatomy, and Pathophysiology clinical class C3 to C6 and a visual analog scale for pain (VAS pain) score >3 were considered eligible. We randomly assigned limbs with ≥50% IVO on IVUS to undergo medical treatment alone or medical treatment plus iliac vein stenting. The patient and clinical physician were blinded. Primary outcomes included change from baseline in VAS pain score, Venous Clinical Severity Score, and 36-Item Short Form Health Survey quality of life questionnaire. Secondary outcomes included stent integrity, migration, and patency rates at 6 months. RESULTS: Of 207 CVD patients, 58 (28%) were eligible and eight (14%) were excluded; 51 of 85 class C3 to C6 limbs (60%) had ≥50% IVO by IVUS. Iliac vein stenting, in randomized patients, was 100% technically successful. At 6 months' follow-up, the mean VAS pain score declined from a median of 8 to 2.5 in patients receiving stents and from 8 to 7 in patients receiving only medical treatment (P < .001). The Venous Clinical Severity Score dropped from a median of 18.5 to 11 after stenting and from 15 to 14 with medical treatment (P < .001). The 36-Item Short Form Health Survey (0-100) improved from a total median score of 53.9 to 85.0 with stenting and 48.3 to 59.8 after medical treatment (P < .001). There was no stent fracture or migration, and the primary, assisted primary, and secondary patency rates were 92%, 96%, and 100%, respectively (median, 11.8; range, 6-18 months). CONCLUSIONS: Endovascular treatment of IVO with stenting is safe and promotes effective relief of symptoms and improvement in quality of life compared with medical treatment alone in symptomatic CVD patients. Our results echo those achieved in numerous previously published nonrandomized clinical series.
引用
- Rossi FH, Kambara AM, Izukawa NM, et al. Randomized double-blinded study comparing medical treatment versus iliac vein stenting in chronic venous disease. J Vasc Surg Venous Lymphat Disord. 2017. PMID: 29292114. doi:10.1016/j.jvsv.2017.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。